Co-Diagnostics, Inc. CODX
Medical/Dental Instruments · IPO 2026 · data as of November 13, 2026
Co-Diagnostics, Inc. (CODX) is a healthcare company listed in the US with a market value of about $3M. In the twelve months to September 30, 2026 it had revenue of $858888 and net income of -$47M, a net margin of -5527.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -62% a year, a 5-year average ROIC of -63%.
About Co-Diagnostics
Co-Diagnostics is listed in the US and classified in medical/dental instruments, IPO year 2026. Revenue went from $7662 in 2017 to $622489 in 2025, growth of about 73.3% a year. It was profitable in 2 of the last 10 years in our data. Its share count rose by 27% over three years (dilution for shareholders). It spends 3074% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $858888 | $622489 | $4M | $7M | $34M | $98M | $75M | $214974 | $39911 | $7662 | — |
| Net income | -$47M | -$47M | -$38M | -$35M | -$14M | $37M | $42M | -$6M | -$6M | -$7M | -$2M |
| Free cash flow | -$27M | -$30M | -$30M | -$23M | $5M | $40M | $27M | -$6M | -$4M | -$3M | -$1M |
| EPS (diluted) | $-21.85 | $-4.41 | $-4.65 | $-4.50 | $-1.69 | $4.61 | $5.70 | $-1.39 | $-1.87 | $-2.36 | $-0.73 |
| Net margin | -5527.6% | -7533.6% | -961.4% | -518.7% | -41.6% | 37.5% | 57.0% | -2882.0% | -15714.3% | -90827.9% | — |
| ROIC | — | -221.8% | -56.5% | -44.7% | -17.7% | 27.5% | 62.4% | -268.0% | -175.2% | -87.3% | -18244.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 1 analysts is $4.00, 1447% above the current price; targets range from $4.00 to $4.00; the consensus rating is “none”; expected EPS is $-3.10 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Co-Diagnostics pay a dividend?
Not currently.
Is Co-Diagnostics a good stock to buy?
We do not give buy or sell advice. Co-Diagnostics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.